Qianwei is a drug produced by Qilu Pharmaceutical for the treatment of male erectile dysfunction (ED). It was approved for marketing in August 2020 and has three specifications: 50mg, 25mg and 0.1g.

Qilu Pharmaceutical aims to safeguard human health, meets social needs as its mission, and relies on advanced science and technology, it is committed to developing and developing drugs that treat common diseases, frequent diseases and many other diseases that seriously endanger human health. The company is headquartered in Jinan City, Shandong Province. It is a large comprehensive modern pharmaceutical enterprise in China. It specializes in the development, production and sales of preparations and raw materials for the treatment of tumors, cardiovascular and cerebrovascular, anti-infection, mental system, nervous system, and ophthalmic diseases.

The company has always adhered to the innovative development strategy, with market demand as the core and product innovation as the leader, widely expanded domestic and foreign scientific research and development cooperation, focused on the introduction and cultivation of talents, and built a high-quality scientific research team with professional and effective R&D capabilities. , has successfully developed nearly 100 national new drugs, established a reasonable product line for the company's future development. Many studies have been awarded national and provincial scientific and technological progress awards and have created good social benefits.

The company has built production bases for preparations, chemical synthesis, biotechnology, antibiotic fermentation and other production workshops, and fully automatic production lines and other major production equipment and testing instruments are purchased from major professional pharmaceutical equipment manufacturers in the world, antibiotic raw materials, Several products such as cephalosporin raw materials and anti-tumor raw materials have already had leading production capacity and production level.

The company has always adhered to the innovative development strategy, with market demand as the core and product innovation as the leader, widely expanded domestic and foreign scientific research and development cooperation, focused on the introduction and cultivation of talents, and built a high-quality scientific research team with strong R&D capabilities. Nearly 100 new drugs have been successfully developed, a reasonable product line under development has been established for the company's future development, and a good social benefit has been created.

The company has built a strict and standardized quality control agency and a complete quality assurance system. It is a GMP certified enterprise of the State Food and Drug Administration. Among them, non-sterile raw materials (fermentation, chemical synthesis), sterile raw materials and various preparations have passed the certification of drug regulatory agencies in the United States, the European Union, Australia, the United Kingdom, South Africa and other countries and regions.

The company's product structure is scientific and complete, with more than 270 products on the market, with a wide range of therapeutic areas and product series. With excellent product quality and wholehearted service tenet to serve customers, it has established the Qilu brand in the field of medicine. It has a world sales network spread across major provinces and cities across the country and sold to North America, the European Union, Japan, Australia and other places, and has a good service to China and the world present trustworthy sincerity.

"The great doctor is sincere and the country is the whole country." The company condenses a unique corporate culture with Qilu characteristics and realizes the common growth of employees and enterprises. While developing rapidly, we have fulfilled all social responsibilities, helped the poor and the needy, and dedicated our love, and demonstrated the development and take-off of China's national pharmaceutical enterprises with brilliant achievements and proud spirit.